| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mustafa Can Şenoymak, Nuriye Hale Erbatur, İrem Şenoymak, Sevde Nur Fıra. The Role of Artificial Intelligence in Endocrine Management: Assessing ChatGPT's Responses to Prolactinoma Queries. Journal of personalized medicine. vol 14. issue 4. 2024-04-27. PMID:38672957. |
this research investigates the utility of chat generative pre-trained transformer (chatgpt) in addressing patient inquiries related to hyperprolactinemia and prolactinoma. |
2024-04-27 |
2024-04-29 |
Not clear |
| Cristina Laguna Benetti-Pinto, Andrea Prestes Nácul, Ana Carolina Japur de Sá Rosa-E-Silva, Gustavo Arantes Rosa Maciel, Vania Dos Santos Nunes Nogueira, Paula Condé Lamparelli Elias, Manoel Martins, Leandro Kasuki, Heraldo Mendes Garmes, Andrea Gleze. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Archives of endocrinology and metabolism. vol 68. 2024-04-05. PMID:38578473. |
dopamine agonists are the first line of treatment for patients with symptomatic hyperprolactinemia due to prolactinomas and in those with idiopathic hyperprolactinemia. |
2024-04-05 |
2024-04-07 |
Not clear |
| Wen-Wen Lin, Guan-Yong Ou, Hui-Fang Dai, Wei-Jiang Zha. Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator. Journal of cellular biochemistry. 2024-03-11. PMID:38465779. |
further investigation into the function of nrg4 and melatonin on prl expression and secretion may provide new clues to advance the clinical control of prolactinomas and hyperprolactinemia. |
2024-03-11 |
2024-03-14 |
human |
| Matheo Augusto Morandi Stumpf, Felipe Moura Maia Pinheiro, Gilberto Ochman Silva, Valter Angelo Sperling Cescato, Nina Rosa Castro Musolino, Malebranche Berardo Carneiro Cunha-Neto, Andrea Gleze. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary. 2023-04-07. PMID:37027090. |
dopamine agonists (da) are the gold-standard for prolactinoma and hyperprolactinemia treatment. |
2023-04-07 |
2023-08-14 |
Not clear |
| Yaron Rudman, Hadar Duskin-Bitan, Ilan Richter, Gloria Tsvetov, Hiba Masri-Iraqi, Amit Akirov, Ilan Shim. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men. Andrology. 2023-03-10. PMID:36897756. |
we hypothesized that a decrease in hemoglobin (hb) levels prior to prolactinoma diagnosis, may signal hyperprolactinemia onset and estimate disease duration. |
2023-03-10 |
2023-08-14 |
Not clear |
| Amit Akirov, Yaron Rudma. The Role of Aromatase Inhibitors in Male Prolactinoma. Journal of clinical medicine. vol 12. issue 4. 2023-02-25. PMID:36835974. |
dopamine agonists are the recommended treatment for male prolactinomas, but some patients may develop dopamine-agonist-resistant hyperprolactinemia, leading to persistent hypogonadism that requires treatment with testosterone. |
2023-02-25 |
2023-08-14 |
Not clear |
| Anna Cho, Greisa Vila, Wolfgang Marik, Sigrid Klotz, Stefan Wolfsberger, Alexander Mick. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else. Frontiers in endocrinology. vol 13. 2022-09-23. PMID:36147567. |
to evaluate the combined predictive value of mri criteria with the prolactin-volume-ratio (pvr) to differentiate prolactinoma from non-prolactinoma, in small sellar lesions with hyperprolactinemia. |
2022-09-23 |
2023-08-14 |
Not clear |
| Anahid Hamidianjahromi, Nicholas A Trito. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Reviews in endocrine & metabolic disorders. 2022-09-20. PMID:36125673. |
dopamine agonists (das) represent a mainstay of therapy for hyperprolactinemia and prolactinomas. |
2022-09-20 |
2023-08-14 |
Not clear |
| Aobo Chen, Chenglong Cao, Bangxin Liu, Shuochen Wang, Shukai Wu, Guozheng Xu, Jian Son. Hyperprolactinemia Associated with Attentional Processing and Interference Control Impairments in Patients with Prolactinomas. Brain sciences. vol 12. issue 8. 2022-08-26. PMID:36009154. |
hyperprolactinemia associated with attentional processing and interference control impairments in patients with prolactinomas. |
2022-08-26 |
2023-08-14 |
human |
| Emmanuel Ssemmondo, Anis Abobaker, Jonathan Tho. Coexisting Prolactin-Secreting Macroadenoma, Hypopituitarism and Type 1 Diabetes Mellitus in a Young Adult Male Patient. Cureus. vol 13. issue 12. 2022-01-24. PMID:35070533. |
these patients might not present with the classical clinical features of hyperprolactinemia, and instead, they present with frequent hypoglycaemia and decreased insulin requirement due to secondary adrenal insufficiency as a consequence of the mass effect of the prolactinoma. |
2022-01-24 |
2023-08-13 |
Not clear |
| Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jian. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders. vol 21. issue 1. 2021-11-18. PMID:34774043. |
prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (das) are generally the first-line treatment for them. |
2021-11-18 |
2023-08-13 |
Not clear |
| Amit Tirosh, Ilan Shimo. Management of macroprolactinomas. Clinical diabetes and endocrinology. vol 1. 2020-10-01. PMID:28702224. |
patients with prolactinoma present with symptoms evolving from hyperprolactinemia and with those caused by pressure of the expanding mass on surrounding tissues, including the optic chiasm and the cavernous sinuses. |
2020-10-01 |
2023-08-13 |
Not clear |
| María Andrea Camilletti, Alejandra Abeledo-Machado, Pablo A Perez, Erika Y Faraoni, Fernanda De Fino, Susana B Rulli, Jimena Ferraris, Daniel Pisera, Silvina Gutierrez, Peter Thomas, Graciela Díaz-Torg. mPRs represent a novel target for PRL inhibition in experimental prolactinomas. Endocrine-related cancer. vol 26. issue 5. 2020-07-21. PMID:30856609. |
moreover, in an in vivo treatment, that allows both, pituitary and hypothalamus actions, the mpr agonist strongly reduced the hyperprolactinemia in transgenic females carrying prolactinoma. |
2020-07-21 |
2023-08-13 |
mouse |
| Adriana G Ioachimescu, Maria Fleseriu, Andrew R Hoffman, T Brooks Vaughan Iii, Laurence Katznelso. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. European journal of endocrinology. vol 180. issue 1. 2019-03-05. PMID:30400048. |
background dopamine agonists (das) are the main treatment for patients with hyperprolactinemia and prolactinomas. |
2019-03-05 |
2023-08-13 |
human |
| Filip Gabalec, Jan Čáp, Jakub Radoch. [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists]. Vnitrni lekarstvi. vol 63. issue 9. 2018-02-20. PMID:29120651. |
the paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease.key words: dopamine agonists - ergolines/adverse effects - heart valve diseases - hyperprolactinemia - pituitary neoplasms - prolactinoma. |
2018-02-20 |
2023-08-13 |
Not clear |
| Rahim Khorassanizadeh, Vishnu Sundaresh, Steven N Levin. Primary Hypothyroidism with Exceptionally High Prolactin-A Really Big Deal. World neurosurgery. vol 91. 2017-09-28. PMID:27155380. |
this combination of hyperprolactinemia and pituitary gland enlargement might raise suspicion for a prolactinoma or a nonfunctioning adenoma limiting the ability of hypothalamic dopamine to inhibit prolactin production, the so-called "stalk effect." |
2017-09-28 |
2023-08-13 |
Not clear |
| Jose Donato, Renata Frazã. Interactions between prolactin and kisspeptin to control reproduction. Archives of endocrinology and metabolism. vol 60. issue 6. 2017-08-16. PMID:27901187. |
pathological hyperprolactinemia is mainly due to the presence of a prolactinoma or pharmacological effects induced by drugs that interact with the dopamine system. |
2017-08-16 |
2023-08-13 |
Not clear |
| Valérie Bernard, Justine Bouilly, Isabelle Beau, Isabelle Broutin, Philippe Chanson, Jacques Young, Nadine Binar. Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. Neuroendocrinology. vol 103. issue 6. 2017-05-15. PMID:26641246. |
the prolactin receptor (prlr) is a good candidate, however, as prlr knockout mice develop prolactinomas, and a case of familial hyperprolactinemia has been linked to prlr mutation. |
2017-05-15 |
2023-08-13 |
mouse |
| E Sala, P Bellaviti Buttoni, E Malchiodi, E Verrua, G Carosi, E Profka, G Rodari, M Filopanti, E Ferrante, A Spada, G Mantovan. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. Journal of endocrinological investigation. vol 39. issue 12. 2017-04-25. PMID:27245604. |
recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. |
2017-04-25 |
2023-08-13 |
Not clear |
| Sema Ciftci Dogansen, Ozlem Soyluk Selcukbiricik, Seher Tanrikulu, Sema Yarma. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary. vol 19. issue 3. 2017-03-22. PMID:26830552. |
the aim of the study was to assess the effect of dopamine agonist (da) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma. |
2017-03-22 |
2023-08-13 |
Not clear |